Xeris Pharmaceuticals (NASDAQ: XERS) is one of 547 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Xeris Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, dividends and profitability.
Earnings & Valuation
This table compares Xeris Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Xeris Pharmaceuticals||$2.46 million||-$60.08 million||-1.92|
|Xeris Pharmaceuticals Competitors||$2.17 billion||$230.01 million||-3.52|
This is a summary of current recommendations and price targets for Xeris Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xeris Pharmaceuticals Competitors||4546||13020||27669||994||2.54|
Xeris Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 155.21%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.43%. Given Xeris Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Xeris Pharmaceuticals is more favorable than its peers.
Institutional and Insider Ownership
40.1% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 46.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.4% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Xeris Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xeris Pharmaceuticals Competitors||-1,760.46%||-120.17%||-28.09%|
Xeris Pharmaceuticals beats its peers on 7 of the 12 factors compared.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.